

Resource Summary Report

Generated by [dkNET](#) on Sep 12, 2026

LUDLU-1

RRID:CVCL_2582

Type: Cell Line

Proper Citation

RRID:CVCL_2582

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2582

Proper Citation: RRID:CVCL_2582

Description: Cell line LUDLU-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung squamous cell carcinoma

Defining Citation: [PMID:2577272](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23226101](#), [PMID:24002593](#), [PMID:24244370](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LUDLU-1

Synonyms: Ludlu-1, LUDLU 1, LUDLU1

Cross References: CLO:CLO_0007417, CLDB:cl3269, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:561, BioSample:SAMN03473041, BioSample:SAMN10987864, cancercellines:CVCL_2582, Cell_Model_Passport:SIDM01363, Cosmic:753591, Cosmic:2060536, DepMap:ACH-000390, ECACC:92012463, EGA:EGAS00001002554, GEO:GSM827451, GEO:GSM887284, GEO:GSM888359, GEO:GSM1374639, IARC_TP53:21483, LiGeA:CCLE_553, LINCS_LDP:LCL-1589, Pharmacodb:LUDLU1_871_2019, Progenetix:CVCL_2582, Wikidata:Q54903257

ID: CVCL_2582

Record Creation Time: 20220427T220737+0000

Record Last Update: 20260905T181048+0000

Ratings and Alerts

No rating or validation information has been found for LUDLU-1.

No alerts have been found for LUDLU-1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Torres-Martínez S, et al. (2024) Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma. *Molecular oncology*, 18(1), 190.

Nguyen T, et al. (2024) TNIK inhibition sensitizes TNIK-overexpressing lung squamous cell carcinoma to radiotherapy. *Molecular cancer therapeutics*.

Torres-Ayuso P, et al. (2021) TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin. *Cancer discovery*, 11(6), 1411.

Oberlick EM, et al. (2019) Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. *Cell reports*, 28(9), 2331.